Skip to main content
SpringerLink
Log in
Book cover

Molecular Pathology in Clinical Practice pp 453–469Cite as

Prostate Cancer

  • Chapter

  • 3546 Accesses

Abstract

The diagnosis and management of prostate cancer (PCa) was revolutionized by monitoring of prostate specific antigen (PSA), with a reduction in the mortality rate for men between the ages of 60 and 79 years, which correlates with a decrease in the incidence of metastatic disease. The monitoring of PSA levels also has led to overdiagnosis of clinically insignificant PCa, while highly aggressive PCa continues to be underrecognized. Over the last decade, advances in gene expression techniques and the introduction of sophisticated bioinformatics tools, have increased the momentum for discovery of more accurate clinicopathologic testing algorithms. Many potentially useful molecular biomarkers are using diverse specimen types, such as blood, urine, and tissue. This chapter describes the biomarkers used for diagnosis and prognosis for PCa.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Flocks RH, Urich VC, Patel CA, Opitz JM. Studies on the antigenic properties of prostatic tissue. I. J Urol. 1960;84:134–43.

    CAS  PubMed  Google Scholar 

  2. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66:8337–41.

    Article  CAS  PubMed  Google Scholar 

  3. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011;50 Suppl 1:61–75.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Bentley DR, Balasubramanian S, Swerdlow HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456:53–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497–511.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437:376–80.

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Shendure J, Porreca GJ, Reppas NB, et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science. 2005;309:1728–32.

    Article  CAS  PubMed  Google Scholar 

  8. Smith DR, Quinlan AR, Peckham HE, et al. Rapid whole-genome mutational profiling using next-generation sequencing technologies. Genome Res. 2008;18:1638–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56:275–86.

    Article  CAS  PubMed  Google Scholar 

  10. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595–9.

    Article  CAS  PubMed  Google Scholar 

  11. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396–400.

    Article  CAS  PubMed  Google Scholar 

  12. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.

    Article  CAS  PubMed  Google Scholar 

  13. Demichelis F, Setlur SR, Beroukhim R, et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer. 2009;48:366–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100:815–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004;101:811–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67:8504–10.

    Article  CAS  PubMed  Google Scholar 

  18. Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. E17K substitution in AKT1 in prostate cancer. Br J Cancer. 2010;102:1491–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Forbes SA, Tang G, Bindal N, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010;38:D652–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Shariat SF, Park S, Trinh QD, Roehrborn CG, Slawin KM, Karakiewicz PI. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. J Urol. 2007;178:1229–36. discussion 36-7.

    Article  CAS  PubMed  Google Scholar 

  21. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239–46.

    Article  CAS  PubMed  Google Scholar 

  22. Stenman UH. Detection of complexes between prostate-specific antigen and protease inhibitors in plasma. Clin Chem. 2010;56:1895–6.

    Article  CAS  PubMed  Google Scholar 

  23. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594–8.

    Article  CAS  PubMed  Google Scholar 

  24. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222–6.

    CAS  PubMed  Google Scholar 

  25. Stenman UH, Leinonen J, Zhang WM. Standardization of PSA determinations. Scand J Clin Lab Invest Suppl. 1995;221:45–51.

    Article  CAS  PubMed  Google Scholar 

  26. Carlsson S, Maschino A, Schroder F, et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur Urol. 2013;64:693–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386–99. discussion 98-9.

    Article  CAS  PubMed  Google Scholar 

  28. Voigt JD, Zappala SM, Vaughan ED, Wein AJ. The Kallikrein Panel for prostate cancer screening: its economic impact. Prostate. 2014;74:250–9.

    Article  PubMed  Google Scholar 

  29. Ulmert D, Becker C, Nilsson JA, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem. 2006;52:235–9.

    Article  CAS  PubMed  Google Scholar 

  30. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008;6:19.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer. 1997;74:630–6.

    Article  CAS  PubMed  Google Scholar 

  32. Abrate A, Lazzeri M, Lughezzani G, et al. Clinical performance of Prostate Health Index (PHI) for prediction of prostate cancer in obese men: data from a multicenter European prospective study, PROMEtheuS project. BJU Int. 2015;115:537–45.

    Article  CAS  PubMed  Google Scholar 

  33. Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem. 2000;275:37397–406.

    Article  CAS  PubMed  Google Scholar 

  34. Gan L, Lee I, Smith R, et al. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene. 2000;257:119–30.

    Article  CAS  PubMed  Google Scholar 

  35. Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun. 2000;276:125–33.

    Article  CAS  PubMed  Google Scholar 

  36. Yousef GM, Diamandis EP. The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics. 2000;65:184–94.

    Article  CAS  PubMed  Google Scholar 

  37. Yousef GM, Magklara A, Diamandis EP. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics. 2000;69:331–41.

    Article  CAS  PubMed  Google Scholar 

  38. Yousef GM, Scorilas A, Diamandis EP. Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics. 2000;63:88–96.

    Article  CAS  PubMed  Google Scholar 

  39. Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family—genomic characterization, mapping, tissue expression and hormonal regulation. Gene. 2000;254:119–28.

    Article  CAS  PubMed  Google Scholar 

  40. Lundwall A, Clauss A, Olsson AY. Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors. Biol Chem. 2006;387:243–9.

    CAS  PubMed  Google Scholar 

  41. Shaw JL, Diamandis EP. Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines. Biol Chem. 2008;389:1409–19.

    CAS  PubMed  Google Scholar 

  42. Denmeade SR, Lovgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate. 2001;48:122–6.

    Article  CAS  PubMed  Google Scholar 

  43. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate. 2001;48:1–6.

    Article  CAS  PubMed  Google Scholar 

  44. Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev. 2010;31:407–46.

    Article  CAS  PubMed  Google Scholar 

  45. Andriole GL, Catalona WJ. Prostate carcinoma. Annu Rev Med. 1994;45:351–9.

    Article  CAS  PubMed  Google Scholar 

  46. Riegman PH, Vlietstra RJ, van der Korput HA, Romijn JC, Trapman J. Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol. 1991;76:181–90.

    Article  CAS  PubMed  Google Scholar 

  47. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol. 1991;5:1921–30.

    Article  CAS  PubMed  Google Scholar 

  48. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol. 1997;11:148–61.

    Article  CAS  PubMed  Google Scholar 

  49. Becker C, Piironen T, Pettersson K, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol. 2000;163:311–6.

    Article  CAS  PubMed  Google Scholar 

  50. Darson MF, Pacelli A, Roche P, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology. 1999;53:939–44.

    Article  CAS  PubMed  Google Scholar 

  51. Haese A, Graefen M, Steuber T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate. 2001;49:101–9.

    Article  CAS  PubMed  Google Scholar 

  52. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology. 2000;55:694–9.

    Article  CAS  PubMed  Google Scholar 

  53. Partin AW, Catalona WJ, Finlay JA, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology. 1999;54:839–45.

    Article  CAS  PubMed  Google Scholar 

  54. Haese A, Graefen M, Becker C, et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate. 2003;54:181–6.

    Article  CAS  PubMed  Google Scholar 

  55. Kurek R, Nunez G, Tselis N, et al. Prognostic value of combined “triple”-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res. 2004;10:5808–14.

    Article  CAS  PubMed  Google Scholar 

  56. Bjartell AS. Next-generation prostate-specific antigen test: ready to use? Eur Urol. 2013;64:700–2.

    Article  PubMed  Google Scholar 

  57. Sartori DA, Chan DW. Biomarkers in prostate cancer: what’s new? Curr Opin Oncol. 2014;26:259–64.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005;15:187–95.

    Article  PubMed  Google Scholar 

  59. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012;61:1096–106.

    Article  PubMed  Google Scholar 

  60. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.

    Article  CAS  PubMed  Google Scholar 

  61. Kattan MW, Vickers AJ, Yu C, et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer. 2009;115:1005–10.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Gupta A, Lotan Y, Ashfaq R, et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol. 2009;55:1124–33.

    Article  CAS  PubMed  Google Scholar 

  63. Shariat SF, Roehrborn CG, McConnell JD, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007;25:349–55.

    Article  CAS  PubMed  Google Scholar 

  64. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate. 1999;39:123–9.

    Article  CAS  PubMed  Google Scholar 

  65. Hienert G, Kirchheimer JC, Pfluger H, Binder BR. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol. 1988;140:1466–9.

    CAS  PubMed  Google Scholar 

  66. Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001;19:2856–64.

    CAS  PubMed  Google Scholar 

  67. Shariat SF, Kattan MW, Traxel E, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10:1992–9.

    Article  CAS  PubMed  Google Scholar 

  68. Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001;92:2985–92.

    Article  CAS  PubMed  Google Scholar 

  69. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med. 1995;1:282–4.

    Article  CAS  PubMed  Google Scholar 

  70. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90:2312–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  71. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6:2702–6.

    CAS  PubMed  Google Scholar 

  72. Karam JA, Svatek RS, Karakiewicz PI, et al. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res. 2008;14:1418–22.

    Article  CAS  PubMed  Google Scholar 

  73. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003;21:3573–9.

    Article  CAS  PubMed  Google Scholar 

  74. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112:315–25.

    Article  PubMed  Google Scholar 

  75. Shariat SF, Karam JA, Walz J, et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res. 2008;14:3785–91.

    Article  CAS  PubMed  Google Scholar 

  76. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975–9.

    CAS  PubMed  Google Scholar 

  77. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–15.

    Article  CAS  PubMed  Google Scholar 

  78. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6:255–61.

    Article  CAS  PubMed  Google Scholar 

  79. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine–a new perspective for detecting prostate cancer. Eur Urol. 2004;46:182–6. discussion 7.

    Article  CAS  PubMed  Google Scholar 

  80. Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010;70:10–6.

    Article  CAS  PubMed  Google Scholar 

  81. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–15. discussion -6.

    Article  CAS  PubMed  Google Scholar 

  82. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–8.

    PubMed  Google Scholar 

  83. Crawford ED, Rove KO, Trabulsi EJ, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012;188:1726–31.

    Article  PubMed  Google Scholar 

  84. Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P. Urinary prostate cancer 3 test: toward the age of reason? Urology. 2010;75:447–53.

    Article  PubMed  Google Scholar 

  85. Auprich M, Bjartell A, Chun FK, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011;60:1045–54.

    Article  CAS  PubMed  Google Scholar 

  86. van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13:939–43.

    Article  PubMed  Google Scholar 

  87. Ankerst DP, Groskopf J, Day JR, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008;180:1303–8. discussion 8.

    Article  PubMed  Google Scholar 

  88. Perdona S, Cavadas V, Di Lorenzo G, et al. Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun’s nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol. 2011;59:81–7.

    Article  PubMed  Google Scholar 

  89. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804–9. discussion 9-10.

    Article  PubMed  Google Scholar 

  90. Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008;180:1975–8. discussion 8-9.

    Article  PubMed  Google Scholar 

  91. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27:253–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  92. Hermans KG, van der Korput HA, van Marion R, et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 2008;68:7541–9.

    Article  CAS  PubMed  Google Scholar 

  93. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 2008;68:3094–8.

    Article  CAS  PubMed  Google Scholar 

  94. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008;14:3380–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008;68:8516–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  96. Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008;27:5348–53.

    Article  CAS  PubMed  Google Scholar 

  97. Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer. 2006;95:767–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  98. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:9234–42.

    Article  CAS  PubMed  Google Scholar 

  99. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69:2912–8.

    Article  CAS  PubMed  Google Scholar 

  100. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.

    Article  CAS  PubMed  Google Scholar 

  101. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8:440–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  102. Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011;19:664–78.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  103. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008;21:1451–60.

    Article  CAS  PubMed  Google Scholar 

  104. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007;13:5103–8.

    Article  CAS  PubMed  Google Scholar 

  105. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3:94ra72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  106. Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011;35:1014–20.

    Article  PubMed Central  PubMed  Google Scholar 

  107. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  108. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011;24:1128–38.

    Article  PubMed  CAS  Google Scholar 

  109. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13:228–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  110. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20:538–44.

    Article  CAS  PubMed  Google Scholar 

  111. Zhang S, Pavlovitz B, Tull J, Wang Y, Deng FM, Fuller C. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol. 2010;19:151–6.

    Article  CAS  PubMed  Google Scholar 

  112. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia. 2006;8:465–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  113. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006;66:8347–51.

    Article  CAS  PubMed  Google Scholar 

  114. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer. 2006;45:717–9.

    Article  CAS  PubMed  Google Scholar 

  115. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26:2667–73.

    Article  CAS  PubMed  Google Scholar 

  116. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene. 2008;27:1993–2003.

    Article  CAS  PubMed  Google Scholar 

  117. Watson RW, Schalken JA. Future opportunities for the diagnosis and treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2004;7 Suppl 1:S8–13.

    Article  CAS  PubMed  Google Scholar 

  118. Ishkanian AS, Mallof CA, Ho J, et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate. 2009;69:1091–100.

    Article  CAS  PubMed  Google Scholar 

  119. Fang Z, Soleymani L, Pampalakis G, et al. Direct profiling of cancer biomarkers in tumor tissue using a multiplexed nanostructured microelectrode integrated circuit. ACS Nano. 2009;3:3207–13.

    Article  CAS  PubMed  Google Scholar 

  120. Kawachi MH, Bahnson RR, Barry M, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010;8:240–62.

    CAS  PubMed  Google Scholar 

  121. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162–200.

    CAS  PubMed  Google Scholar 

  122. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 2010;8:145.

    PubMed  Google Scholar 

  123. Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:690.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  124. Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol. 2014;192:409–14.

    Article  PubMed  Google Scholar 

  125. Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:848–53.

    Article  PubMed Central  PubMed  Google Scholar 

  126. Van Neste L, Bigley J, Toll A, et al. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol. 2012;12:16.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  127. Stewart GD, Van Neste L, Delvenne P, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013;189:1110–6.

    Article  PubMed  Google Scholar 

  128. Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014;192:1081–7.

    Article  PubMed Central  PubMed  Google Scholar 

  129. Alimonti A, Carracedo A, Clohessy JG, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42:454–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  130. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007;97:678–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  131. Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 2009;218:505–13.

    Article  CAS  PubMed  Google Scholar 

  132. Koksal IT, Dirice E, Yasar D, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol. 2004;22:307–12.

    Article  CAS  PubMed  Google Scholar 

  133. Koksal IT, Yasar D, Dirice E, et al. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol Int. 2005;75:102–6.

    Article  CAS  PubMed  Google Scholar 

  134. Reid AH, Attard G, Ambroisine L, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010;102:678–84.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  135. Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology. 2012;60:645–52.

    Article  PubMed  Google Scholar 

  136. Bismar TA, Yoshimoto M, Vollmer RT, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int. 2011;107:477–85.

    Article  PubMed  Google Scholar 

  137. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst. 2003;95:661–8.

    Article  CAS  PubMed  Google Scholar 

  138. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011;29:3669–76.

    Article  PubMed  Google Scholar 

  139. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol. 2014;65:1023–31.

    Article  PubMed  Google Scholar 

  140. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005–12.

    Article  PubMed Central  PubMed  Google Scholar 

  141. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–71.

    Article  CAS  PubMed  Google Scholar 

  142. Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer. 2002;1:90–6.

    Article  PubMed  Google Scholar 

  143. Kattan MW, Scardino PT. Prostate cancer: nomograms and risk assessment models. J Natl Compr Canc Netw. 2003;1 Suppl 3:S-49–54.

    Google Scholar 

  144. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008;68(1):73–80.

    Google Scholar 

  145. Han B, Mehra R, Dhanasekaran SM, Yu J, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008;68(18):7629–37.

    Google Scholar 

  146. Rickman DS, Pflueger D, Moss B, et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res. 2009;69(7):2734–8.

    Google Scholar 

  147. Pflueger D, Rickman DS, Sboner A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia. 2009;11(8):804–11.

    Google Scholar 

  148. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pathology and Laboratory Medicine, Anatomic Pathology, University of Pennsylvania, 6 Founders Bldg., 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Priti Lal M.D., F.A.C.P.

Authors
  1. Priti Lal M.D., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Priti Lal M.D., F.A.C.P. .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, University of Vermont College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA

    Debra G.B. Leonard

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lal, P. (2016). Prostate Cancer. In: Leonard, D. (eds) Molecular Pathology in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-19674-9_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19674-9_35

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19673-2

  • Online ISBN: 978-3-319-19674-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation